Abstract:
BACKGROUND:Estimates of WHO and UNICEF vaccination coverage may provide little insight into the extent to which vaccinations are administered on time. Yet, lack of adherence to the recommended age to receive a specific vaccination may have detrimental health consequences. For example, delays in receiving vaccination will prolong the risk of lack of protection, often when disease risk is highest, such as during early infancy. We estimated the reported age at vaccination, and vaccine coverage at different ages in children from five sub-Saharan African countries. METHODS:We analyzed data from the latest Demographic and Health Programme databases available for Burkina Faso 2010 (n=15,044 observations), Ghana 2008 (n=2992), Kenya 2008-9 (n=6079), Senegal 2010-11 (n=12,326), and Tanzania 2010 (n=8023). We assessed, amongst vaccinees, the exact age when vaccine was administered for the three infant doses of pentavalent vaccine (DTP) and the first dose of measles-containing-vaccine (MCV), as well as the proportion of children immunized with these antigens by a certain age. Vitamin A supplementation (VAS) coverage was evaluated as a potential contact visit for vaccine introduction. RESULTS:For all DTP doses, the median intervals between recommended and actual ages of receiving vaccination ranged from 12, 17 and 23 days in Kenya, to 22, 33 and 45 days in Senegal. MCV was mostly given during the recommended age of 9 months. In each country, there was a large discrepancy in the median age at DTP vaccination between regions. VAS coverage in young children ranged from 30.3% in Kenya to 78.4% in Senegal, with large variations observed between areas within each study country. CONCLUSION:In the context of new vaccine introduction, age of children at vaccination should be monitored to interpret data on vaccine-preventable disease burden, vaccine effectiveness, and vaccine safety, and to adapt targeted interventions and messages.
journal_name
Vaccinejournal_title
Vaccineauthors
Delrieu I,Gessner BD,Baril L,Roset Bahmanyar Edoi
10.1016/j.vaccine.2015.10.107subject
Has Abstractpub_date
2015-12-16 00:00:00pages
7290-7298issue
51eissn
0264-410Xissn
1873-2518pii
S0264-410X(15)01563-7journal_volume
33pub_type
杂志文章相关文献
VACCINE文献大全abstract::Although West Nile virus (WNV) causes annual cases of neurological disease and deaths in humans, a vaccine has not been licensed for human use. Several WNV genes have been targeted for mutagenesis in attempts to generate live attenuated vaccine candidates, including the non-structural protein NS5. Specifically, mutati...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2019.09.045
更新日期:2019-11-15 00:00:00
abstract::Two outbreaks of hepatitis A started almost simultaneously in a maternal school and in a day care centre located at opposite sides of Florence, Italy, at the end of 2002. Both of them originated from immigrant children, and in both cases, hepatitis A was initially not recognised due to aspecific symptoms. While vaccin...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2005.01.044
更新日期:2005-03-18 00:00:00
abstract::Sin Nombre virus (SNV; family Bunyaviridae, genus Hantavirus) causes a hemorrhagic fever known as hantavirus pulmonary syndrome (HPS) in North America. There have been approximately 200 fatal cases of HPS in the United States since 1993, predominantly in healthy working-age males (case fatality rate 35%). There are no...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2013.07.025
更新日期:2013-09-13 00:00:00
abstract::A cost-effectiveness analysis of the introduction of acellular pertussis booster doses at either 4 or 15 years of age was performed. A transmission dynamic model was used to predict the level of indirect protection in those too young to be vaccinated. Multivariate sensitivity analyses were performed. In England and Wa...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/s0264-410x(01)00473-x
更新日期:2002-01-31 00:00:00
abstract::Protein C deletion mutants of West Nile virus (WNV) were evaluated for their potential use as live virus vaccine candidates in vivo. Double and triple mutants carrying small deletions and second-site point mutations, as well as mutants with large deletions of 36 and 37 amino acid residues were tested in a stringent mo...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2010.06.045
更新日期:2010-08-16 00:00:00
abstract::Two cross-sectional population-based telephone surveys interviewed 877 and 1,103 respondents aged >or=65. When compared to the first survey, respondents of the second survey were more likely to have heard of influenza vaccination (IV) (adjusted OR=4.09), to have received IV (adjusted OR=2.04) or to have done so in the...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2007.09.047
更新日期:2007-11-28 00:00:00
abstract::Oral poliovirus vaccine (OPV) is tested for safety by evaluation of neurovirulence in rhesus and cynomolgus macaques. After intraspinal or intrathalamic injection of varying doses of vaccine, monkeys are followed for 17-21 days, killed, and a histopathological evaluation is made of the severity of poliomyelitis lesion...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/0264-410x(92)90396-2
更新日期:1992-01-01 00:00:00
abstract::Two compound Chinese herbal medicinal ingredients (cCHMIs) were prepared, respectively, with epimedium polysaccharide plus propolis flavone (cCHMIs 1) and astragalus polysaccharide plus ginsenoside (cCHMIs 2). In animal immune experiment, Newcastle disease vaccine was mixed, respectively, with two cCHMIs and IL-2 to v...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2006.07.005
更新日期:2006-11-30 00:00:00
abstract:OBJECTIVE:To assess whether recipients and non-recipients of the human papillomavirus (HPV) vaccine subsequently differ in terms of sexual risk taking behaviour. DESIGN:Cross-sectional survey. Sequential analyses constructed from self-reported age at vaccination, age at first intercourse and age at response. SETTING:...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2014.07.025
更新日期:2014-09-03 00:00:00
abstract::A human hookworm vaccine is under development and in clinical trials in Africa and the Americas. The vaccine contains the Na-APR-1 and Na-GST-1 antigens. It elicits neutralizing antibodies that interfere with establishment of the adult hookworm in the gut and the ability of the parasite to feed on blood. The vaccine t...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2016.03.078
更新日期:2016-06-03 00:00:00
abstract::Rabies is an ancient zoonosis that continues to be an important health problem worldwide. Vaccination with rabies vaccine is the most important strategy to prevent rabies. Adjuvants contribute to the immune response of viral vaccine. The aim of this study was to investigate whether artemisinin derivatives artesunate a...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2019.09.077
更新日期:2019-12-03 00:00:00
abstract:BACKGROUND:The Global Vaccine Action Plan highlights the need for immunisation programmes to have sustainable access to predictable funding. A good understanding of current and future funding needs, commitments, and gaps is required to enhance planning, improve resource allocation and mobilisation, and to avoid funding...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2014.12.053
更新日期:2015-05-07 00:00:00
abstract::The effectiveness of HPV vaccine against HSIL+ (pathologically diagnosed CIN2+) in the first cohort in Japan was investigated in 22,743 women aged 20 to 29 years (parts of national cervical cancer screening program of FY [fiscal year] 2015, the Japan Cancer Society). Vaccinated women had a statistically significant 69...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2018.05.048
更新日期:2018-12-18 00:00:00
abstract::A novel vaccine concept is discussed based on recent evidence of a "back-boost" effect in Influenza infection. The initial immune response to the infection is imprinted through an immune memory pathway. The immune memory in the back-boost mechanism could be used in reversed order as a "forward-boost" in the proposed v...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2015.05.035
更新日期:2015-06-26 00:00:00
abstract::As companies, countries, and governments consider investments in vaccine production for routine immunization and outbreak response, understanding the complexity and cost drivers associated with vaccine production will help to inform business decisions. Leading multinational corporations have good understanding of the ...
journal_title:Vaccine
pub_type: 杂志文章,评审
doi:10.1016/j.vaccine.2017.06.003
更新日期:2017-07-24 00:00:00
abstract:BACKGROUND:Hepatitis B (HepB) vaccination is the most effective measure to prevent HBV infection. Routine HepB vaccination was recommended for infants in 1991 and catch-up vaccination has been recommended for adolescents since in 1995. The purpose of this study is to assess HepB vaccination among adolescents 13-17 year...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2015.02.021
更新日期:2015-04-08 00:00:00
abstract::This paper presents the results of a global survey that aimed to collect information on country's immunization policy development processes, particularly on the presence and function of national Immunization Technical Advisory Groups (ITAGs). Characteristics of national ITAGs are described as well as attributes of the...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2009.07.089
更新日期:2010-04-19 00:00:00
abstract::Nowadays health care worker (HCW) vaccination is widely recommended. Although the benefits of this strategy have been demonstrated in long-term care settings, no studies have been performed in regular hospital departments. We adapt a previously developed model of influenza transmission in a long-term care nursing home...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2009.07.104
更新日期:2009-10-19 00:00:00
abstract::In 2005, in accordance with recommendations made by the European Medicines Agency, the Italian Drug Agency ordered withdrawal of the hexavalent Hexavac(®) vaccine (Sanofi Pasteur MSD) from the market. Concerns had been raised about the low immunogenicity of the hepatitis B virus component of the vaccine, assessed by m...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2012.11.029
更新日期:2013-01-07 00:00:00
abstract::In this investigation we have generated and defined the immunogenicity of two novel HIV/AIDS vaccine candidates based on the highly attenuated vaccinia virus strains, MVA and NYVAC, efficiently expressing in the same locus (TK) and under the same viral promoter the codon optimized HIV-1 genes encoding gp120 and Gag-Po...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2006.09.090
更新日期:2007-04-12 00:00:00
abstract::Vaccination strategies against Klebsiella pneumoniae have largely focussed on the polysaccharide capsule. However, the large number and high prevalence of individual capsular serotypes limits the widespread applicability of capsule-based vaccines. This study establishes that immunization with purified LPS can protect ...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2008.07.100
更新日期:2008-10-16 00:00:00
abstract:BACKGROUND:Influenza A/H7N9 viruses are undergoing antigenic drift since their emergence in 2013, and vaccination strategies are needed for pandemic preparedness. Two doses of adjuvanted monovalent inactivated influenza A/H7N9 vaccine (IIV1 A/H7N9) are needed for optimal serological responses. However, administering 2 ...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2019.03.071
更新日期:2019-05-01 00:00:00
abstract::In this study, a recombinant truncated West Nile virus envelope protein antigen (rWNV-E) was produced in serum-free cultures of the expresSF+ insect cell line via baculovirus infection. This production system was selected based on its use in the production of candidate human and animal vaccine antigens. A defined ferm...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2008.10.046
更新日期:2009-01-07 00:00:00
abstract::Live cold-adapted recombinant bivalent vaccine of influenza type A was studied in a controlled field trial in 1982-1983 among nearly 30,000 children 3-15 years old. The bivalent vaccine consisted of recombinants 47/25/1 (H1N1) and 47/7/2 (H3N2) of wild-type viruses A/Brazil/11/78 (H1N1) and A/Bangkok/1/79 (H3N2) with ...
journal_title:Vaccine
pub_type: 临床试验,杂志文章
doi:10.1016/0264-410x(86)90049-6
更新日期:1986-06-01 00:00:00
abstract:BACKGROUND:Combination antiretroviral therapy (cART) is the main therapeutic management tool for HIV/AIDS. Despite its success in controlling viral load and disease progression, cART is expensive, associated with a range of significant side effects and depends for its efficacy on the patient's life-long commitment to h...
journal_title:Vaccine
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1016/j.vaccine.2013.09.057
更新日期:2013-11-19 00:00:00
abstract::The purpose of the NIAID/FDA joint workshop, "correlates of immunity for pneumococcal conjugate vaccines (PCVs)," was to discuss the present understanding of protective immunity against invasive pneumococcal disease and identify in vitro measures that may represent immunologic correlates in future clinical trials. Ani...
journal_title:Vaccine
pub_type: 杂志文章,评审
doi:10.1016/s0264-410x(03)00025-2
更新日期:2003-05-16 00:00:00
abstract::Crimean-Congo hemorrhagic fever virus (CCHFV) poses a great threat to public health due to its high mortality and transmission rate and wide geographical distribution. There is currently no specific antiviral therapy for CCHF. This study provides the first in-depth analysis of the cellular and humoral immune response ...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2012.08.003
更新日期:2012-09-28 00:00:00
abstract:BACKGROUND:In early 2011, following an increased number of reports of severe vaccine-related injection site reactions, Australian authorities recommended against administering repeat doses of the 23-valent pneumococcal polysaccharide vaccine (23vPPV) in otherwise healthy adults. The aim of this study was to assess a so...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/j.vaccine.2017.01.063
更新日期:2017-03-13 00:00:00
abstract::The use of vaccinia virus in recombinant systems may result in the occurrence of complications observed following smallpox vaccination. The results are presented of a large survey carried out in the USSR between 1968 and 1979. High complication rates are reported, particularly in older primary vaccinees; for example, ...
journal_title:Vaccine
pub_type: 杂志文章
doi:10.1016/0264-410x(92)90023-d
更新日期:1992-01-01 00:00:00
abstract:BACKGROUND:A randomized trial demonstrated that a high-dose inactivated influenza vaccine (IIV-HD) was 24.2% more efficacious than a standard-dose vaccine (IIV-SD) against laboratory-confirmed influenza illness in adults ≥65 years. To evaluate the consistency of IIV-HD benefits, supplemental analyses explored efficacy ...
journal_title:Vaccine
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1016/j.vaccine.2015.07.003
更新日期:2015-08-26 00:00:00